

Global In Silico Clinical Trials Market Report and Forecast 2023-2031

Market Report | 2023-07-07 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global In Silico Clinical Trials Market Report and Forecast 2023-2031

Global In Silico Clinical Trials Market Outlook:

The global in silico clinical trials market size was valued at USD 3.1 billion in 2022, driven by the rise in demand of personalized medicine across the globe. The market size is anticipated to grow at a CAGR of 7.42% during the forecast period of 2023-2031 to achieve a value of USD 6 billion by 2031.

In Silico Clinical Trials: Introduction

In Silico Clinical Trials (ISCT) is an emerging field that utilizes computer modeling and simulation techniques to conduct virtual clinical trials. Unlike traditional clinical trials, which involve testing new drugs or medical interventions on human subjects, ISCT leverages computational models to simulate the behavior of drugs, medical devices, or treatment strategies in virtual patient populations.

ISCT offers several advantages over conventional clinical trials. It allows researchers to explore a wide range of scenarios, predict the outcomes of different treatment strategies, and optimize clinical trial designs before conducting costly and time-consuming human trials. It also enables the assessment of the safety and efficacy of interventions in diverse patient populations, including those with rare diseases or specific genetic profiles.

Key Trends in the Global in Silico Clinical Trials Market

There are several key trends in the market and some of them are:

- Increasing Adoption of Artificial Intelligence and Machine Learning: Artificial intelligence (AI) and machine learning (ML) technologies are being integrated into ISCT to enhance the accuracy and predictive capabilities of the models. These advanced algorithms can analyze large datasets, identify patterns, and make predictions about treatment outcomes, helping to optimize clinical trial designs and personalize treatment approaches.
- Integration of Real-World Data: Real-world data, including electronic health records, wearable device data, and genomic information, are being incorporated into ISCT models. By leveraging this real-world data, researchers can enhance the realism and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

validity of the virtual patient populations, enabling more accurate predictions of treatment responses and outcomes.

-□Regulatory Framework Development: Regulatory bodies are recognizing the potential of ISCT and working towards developing guidelines and frameworks to ensure the reliability, validity, and regulatory acceptance of in silico trial results. These efforts aim to establish standards and protocols for model validation, data quality, and transparency in ISCT, enabling their use in regulatory decision-making processes.

-□Collaboration and Partnerships: Collaboration among academia, industry, and regulatory bodies is becoming more prevalent in the field of ISCT. These collaborations facilitate the sharing of knowledge, expertise, and resources, leading to the development of more robust and reliable in silico trial platforms. It also helps to address the challenges associated with data availability, model validation, and regulatory acceptance.

-□Ethical Considerations and Patient Engagement: As ISCT progresses, ethical considerations related to data privacy, informed consent, and patient rights are gaining attention. Patient engagement in the development and implementation of ISCT models and their participation in decision-making processes are key trends to ensure that the technology aligns with patient values and preferences.

Global In Silico Clinical Trials Market Segmentations

Market Breakup by Industry Type

- Medical Devices
- Pharmaceuticals

Market Breakup by Therapeutic Area

- Oncology
- Infectious Disease
- Hematology
- Cardiology
- Dermatology
- Neurology
- Diabetes
- Others

Market Breakup by Phase

- Phase I
- Phase II
- Phase III
- Phase IV

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global In Silico Clinical Trials Market Scenario

The market for in silico clinical trials (ISCT) is experiencing significant growth and is poised for further expansion in the coming years. ISCT offers a paradigm shift in the way clinical trials are conducted, bringing numerous benefits to the healthcare and pharmaceutical industries. The market is driven by the increasing need for more efficient, cost-effective, and personalized drug

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

development processes.

ISCT eliminates many of the challenges associated with traditional clinical trials, such as the high cost, lengthy timelines, and ethical concerns related to human subjects. By conducting virtual trials using computational models, ISCT enables researchers to explore a wide range of scenarios, optimize trial designs, and make more informed decisions before moving to human trials. This approach leads to faster drug development, reduced costs, and improved patient safety.

One of the key factors driving the market growth is the rapid advancements in technology, particularly in artificial intelligence, machine learning, and big data analytics. These technologies enhance the accuracy and predictive capabilities of ISCT models, enabling researchers to analyze vast amounts of data, identify patterns, and generate insights for drug discovery and development. The integration of real-world data further enhances the realism and applicability of ISCT models, allowing for more personalized treatment strategies.

In conclusion, the market for In Silico Clinical Trials is rapidly growing, driven by technological advancements, regulatory support, and collaborations among stakeholders. The adoption of ISCT promises to revolutionize the drug development process, enabling faster and more cost-effective trials while prioritizing patient safety and personalized treatment approaches. As the market continues to evolve, further advancements in technology, regulatory frameworks, and collaborative efforts will shape its trajectory and unlock its full potential.

Global In Silico Clinical Trials Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Dassault Systemes SE
- Certara Inc.
- Insilico Medicine
- GNS Healthcare Inc.
- The AnyLogic Company
- Novadiscovery SAS
- InSilicoTrials Technologies SpA
- Immunetrics Inc.
- CATO SMS
- Evotec SE

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1□Preface
- 1.1□Objectives of the Study
- 1.2□Key Assumptions
- 1.3□Report Coverage - Key Segmentation and Scope
- 1.4□Research Methodology
- 2□Executive Summary
- 3□Global In Silico Clinical Trials Market Overview
- 3.1□Global In Silico Clinical Trials Market Historical Value (2016-2022)
- 3.2□Global In Silico Clinical Trials Market Forecast Value (2023-2031)
- 4□Global In Silico Clinical Trials Market Dynamics
- 4.1□Market Drivers and Constraints
- 4.2□SWOT Analysis
- 4.3□Porter's Five Forces Model
- 4.4□Key Demand Indicators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.5□Key Price Indicators
- 4.6□Industry Events, Initiatives, and Trends
- 4.7□Value Chain Analysis
- 5□Global In Silico Clinical Trials Market Segmentation
- 5.1□Global In Silico Clinical Trials Market by Industry Type
- 5.1.1□Market Overview
- 5.1.2□Medical Devices
- 5.1.3□Pharmaceuticals
- 5.2□Global In Silico Clinical Trials Market by Therapeutic Area
- 5.2.1□Market Overview
- 5.2.2□Oncology
- 5.2.3□Infectious Disease
- 5.2.4□Hematology
- 5.2.5□Cardiology
- 5.2.6□Dermatology
- 5.2.7□Neurology
- 5.2.8□Diabetes
- 5.2.9□Others
- 5.3□Global In Silico Clinical Trials Market by Phase
- 5.3.1□Market Overview
- 5.3.2□Phase I
- 5.3.3□Phase II
- 5.3.4□Phase III
- 5.3.5□Phase IV
- 5.4□Global In Silico Clinical Trials Market by Region
- 5.4.1□Market Overview
- 5.4.2□North America
- 5.4.3□Europe
- 5.4.4□Asia Pacific
- 5.4.5□Latin America
- 5.4.6□Middle East and Africa
- 6□North America In Silico Clinical Trials Market
- 6.1□Market Share by Country
- 6.2□United States of America
- 6.3□Canada
- 7□Europe In Silico Clinical Trials Market
- 7.1□Market Share by Country
- 7.2□United Kingdom
- 7.3□Germany
- 7.4□France
- 7.5□Italy
- 7.6□Others
- 8□Asia Pacific In Silico Clinical Trials Market
- 8.1□Market Share by Country
- 8.2□China
- 8.3□Japan
- 8.4□India

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5 ASEAN
- 8.6 Australia
- 8.7 Others
- 9 Latin America In Silico Clinical Trials Market
 - 9.1 Market Share by Country
 - 9.2 Brazil
 - 9.3 Argentina
 - 9.4 Mexico
 - 9.5 Others
 - 10 Middle East and Africa In Silico Clinical Trials Market
 - 10.1 Market Share by Country
 - 10.2 Saudi Arabia
 - 10.3 United Arab Emirates
 - 10.4 Nigeria
 - 10.5 South Africa
 - 10.6 Others
 - 11 Patent Analysis
 - 11.1 Analysis by Type of Patent
 - 11.2 Analysis by Publication year
 - 11.3 Analysis by Issuing Authority
 - 11.4 Analysis by Patent Age
 - 11.5 Analysis by CPC Analysis
 - 11.6 Analysis by Patent Valuation
 - 11.7 Analysis by Key Players
 - 12 Grants Analysis
 - 12.1 Analysis by year
 - 12.2 Analysis by Amount Awarded
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Grant Application
 - 12.5 Analysis by Funding Institute
 - 12.6 Analysis by NIH Departments
 - 12.7 Analysis by Recipient Organization
 - 13 Funding Analysis
 - 13.1 Analysis by Funding Instances
 - 13.2 Analysis by Type of Funding
 - 13.3 Analysis by Funding Amount
 - 13.4 Analysis by Leading Players
 - 13.5 Analysis by Leading Investors
 - 13.6 Analysis by Geography
 - 14 Partnership and Collaborations Analysis
 - 14.1 Analysis by Partnership Instances
 - 14.2 Analysis by Type of Partnership
 - 14.3 Analysis by Leading Players
 - 14.4 Analysis by Geography
 - 15 Regulatory Framework
 - 15.1 Regulatory Overview
 - 15.1.1 US FDA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.2 EU EMA
- 15.1.3 INDIA CDSCO
- 15.1.4 JAPAN PMDA
- 15.1.5 Others
- 16 Supplier Landscape
 - 16.1 Dassault Systemes SE
 - 16.1.1 Financial Analysis
 - 16.1.2 Product Portfolio
 - 16.1.3 Demographic Reach and Achievements
 - 16.1.4 Mergers and Acquisitions
 - 16.1.5 Certifications
 - 16.2 Certara Inc.
 - 16.2.1 Financial Analysis
 - 16.2.2 Product Portfolio
 - 16.2.3 Demographic Reach and Achievements
 - 16.2.4 Mergers and Acquisitions
 - 16.2.5 Certifications
 - 16.3 Insilico Medicine
 - 16.3.1 Financial Analysis
 - 16.3.2 Product Portfolio
 - 16.3.3 Demographic Reach and Achievements
 - 16.3.4 Mergers and Acquisitions
 - 16.3.5 Certifications
 - 16.4 GNS Healthcare Inc.
 - 16.4.1 Financial Analysis
 - 16.4.2 Product Portfolio
 - 16.4.3 Demographic Reach and Achievements
 - 16.4.4 Mergers and Acquisitions
 - 16.4.5 Certifications
 - 16.5 The AnyLogic Company
 - 16.5.1 Financial Analysis
 - 16.5.2 Product Portfolio
 - 16.5.3 Demographic Reach and Achievements
 - 16.5.4 Mergers and Acquisitions
 - 16.5.5 Certifications
 - 16.6 Novartis SAS
 - 16.6.1 Financial Analysis
 - 16.6.2 Product Portfolio
 - 16.6.3 Demographic Reach and Achievements
 - 16.6.4 Mergers and Acquisitions
 - 16.6.5 Certifications
 - 16.7 InSilicoTrials Technologies SpA
 - 16.7.1 Financial Analysis
 - 16.7.2 Product Portfolio
 - 16.7.3 Demographic Reach and Achievements
 - 16.7.4 Mergers and Acquisitions
 - 16.7.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.8□Immunetrics Inc.
- 16.8.1□Financial Analysis
- 16.8.2□Product Portfolio
- 16.8.3□Demographic Reach and Achievements
- 16.8.4□Mergers and Acquisitions
- 16.8.5□Certifications
- 16.9□CATO SMS
- 16.9.1□Financial Analysis
- 16.9.2□Product Portfolio
- 16.9.3□Demographic Reach and Achievements
- 16.9.4□Mergers and Acquisitions
- 16.9.5□Certifications
- 16.10□Evotec SE
- 16.10.1□Financial Analysis
- 16.10.2□Product Portfolio
- 16.10.3□Demographic Reach and Achievements
- 16.10.4□Mergers and Acquisitions
- 16.10.5□Certificationsa
- 17□Global In Silico Clinical Trials Market - Distribution Model (Additional Insight)
- 17.1□Overview
- 17.2□Potential Distributors
- 17.3□Key Parameters for Distribution Partner Assessment
- 18□Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19□Company Competitiveness Analysis (Additional Insight)
- 19.1□Very Small Companies
- 19.2□Small Companies
- 19.3□Mid-Sized Companies
- 19.4□Large Companies
- 19.5□Very Large Companies
- 20□Payment Methods (Additional Insight)
- 20.1□Government Funded
- 20.2□Private Insurance
- 20.3□Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global In Silico Clinical Trials Market Report and Forecast 2023-2031

Market Report | 2023-07-07 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-21"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com